

Role of Ivermectin in contrast to other Anti-viral Drugs for the Treatment and Management of Coronavirus Disease in Hospitalized Patients at Wah Cantt: An Institutional Study

L. U. KHATTAK¹ and S. M. ZAHRA^{1,2}

1. Environmental Design, Health and Nutritional Sciences, Allama Iqbal Open University, Islamabad, Pakistan
2. Institute of Food Science and Nutrition, University of Sargodha, Sargodha, Pakistan



BACKGROUND


Complexities faced by Covid patients call for a good cure to relieve patients from painful symptoms (Elgazzar et al., 2020). We observed and recorded the outcomes of the use of ivermectin (IVM) in hospitalized patients with coronavirus disease 2019 (COVID-19) in two tertiary care hospitals.

OBJECTIVE

To know the role of ivermectin in control of covid-19 severity, and to compare the patient recovery/ mortality ratio with and without ivermectin use during hospital stay.

METHODS

With approval and permission of the hospitals management we observed and collected the data as institutional study. Assessed the outcomes and results of Ivermectin on adult patients with COVID-19 admitted in isolation wards. Study period was March 1st 2021 to June 1st 2021 for 90 Days. Primary outcomes were all-cause mortality rate, length of hospital stay, and adverse events. Secondary outcomes included viral clearance and severity of the disease. The risk of bias (RoB) was evaluated using the Cochrane Risk of Bias 2.0 tool. Inverse variance random analysis was performed, with quality of evidence evaluated using GRADE methods consisting of fully recovery, moderate, mild, severer symptoms of Covid 19. Total patients were 200.



The vitals of the patients were studied and recorded, medicine history was taken. And the attention was given to specific use of ivermectin in contrast with other antiviral drugs like remdesivir.

RESULTS

COVID-19 disease severity was mild in 100 patients, moderate in 30, and mild and moderate in 10, 10 patients were with maximum severity even after the use of ivermectin.

Ivermectin seems to reduce all-cause mortality rates compared with non ivermectin use patients as relative risk of 75%.

Recovery ratio of patients with ivermectin therapy was increased and more as compare to other group.

Post covid complications were on low ratio in patients with ivermectin use, while these complications were very common in patients who were not given ivermectin during treatment phase.


DISCUSSION

Popp et al. (2021) supports use of ivermectin for preventing and treating COVID-19. Schmith et al. (2020) condemns the alone use of ivermectin for treating Covid 19

CONCLUSIONS

Comparison showed that ivermectin use reduce all-cause mortality, severity of disease, morbidity in patients and getting them with mostly mild Covid-19 recovery. Ivermectin has an effect on severity of covid 19 or hospital stay time and is a viable option to treat patients with COVID-19.

Diseases Intensity impacted by Ivermectin intervention



	Patients with IVERMECTIN (n=150)	Patients with NON-IVERMECTIN (n=50)
Hospital stay length (Days)		
8-10	50	3
10-14	70	10
14-18	20	17
18-21	10	20
Mortality Rate (%)	25	75
Post-Covid Complications (%)	30	70

REFERENCES

1. Elgazzar A, Hany B, Youssef SA, Hafez M, Moussa H, Eltaweel A. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. 2020.
2. Popp M, Stegemann M, Metzendorf MI, Gould S, Kranke P, Meybohm P, Skoetz N, Weibel S. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews. 2021(7).
3. Schmith VD, Zhou J, Lohmer LR. The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19. Clinical Pharmacology & Therapeutics. 2020 Oct;108(4):762-5.

ACKNOWLEDGEMENT

We are thankful to NHNF Pakistan & NUTRITION TIMES for their support and contribution during research

CONTACT INFORMATION

Dr. Latif Ullah Khattak Email: dlukhattak@gmail.com

Dr. Syeda Mahvish Zahra Email: mahvish.zahra@aiou.edu.pk